New drug combinations of a n.a.r.i., preferably reboxetine,...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/535 (2006.01)

Patent

CA 2326105

This patent application describes a new combination treatment of selective, noradrenaline-reuptake inhibitors (NARI) and specifically, reboxetine, and pindolol to provide rapid relief to patients suffering from depression, general anxiety, attention deficit hyperactivity disorder (ADHD), anxiety disorders such as obsessive compulsive disorders (OCD), panic disorders (PD), social phobia (SD) and the like.

L'invention concerne une nouveau traitement combiné dans lequel on utilise des d'inhibiteurs sélectifs du recaptage de la noradrénaline (NARI) et spécifiquement, de la reboxétine, et du pindolol, pour soulager rapidement des patients souffrant de dépression, d'anxiété générale, d'hyperactivité avec déficit de l'attention, de troubles de l'anxiété, tels que les troubles obsessivo-compulsifs, de troubles de panique, de phobie sociale et similaire.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

New drug combinations of a n.a.r.i., preferably reboxetine,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with New drug combinations of a n.a.r.i., preferably reboxetine,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and New drug combinations of a n.a.r.i., preferably reboxetine,... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1436635

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.